-
公开(公告)号:US20030078410A1
公开(公告)日:2003-04-24
申请号:US10245644
申请日:2002-09-17
发明人: Adolfo Garcia-Sastre , Peter Palese
IPC分类号: C07H021/04 , A61K039/17 , C12N007/01 , C12N015/09 , C12N015/70 , A61K039/00 , C12N007/00 , C12N015/00 , C12N015/63 , C12N015/74
CPC分类号: C07K14/005 , A61K39/00 , A61K48/00 , A61K2039/523 , C12N2760/18122 , C12N2760/18134 , Y02A50/464
摘要: This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I.
-
公开(公告)号:US20030157131A1
公开(公告)日:2003-08-21
申请号:US10314569
申请日:2002-12-09
IPC分类号: C12P021/06 , A61K039/12 , A61K039/145 , C12N015/00 , C12N015/09 , C12N015/63 , C12N015/70 , C12N015/74
CPC分类号: C12N7/00 , A61K39/12 , A61K39/145 , A61K2039/525 , A61K2039/5254 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N2760/16121 , C12N2760/16122 , C12N2760/16132 , C12N2760/16134 , C12N2760/16161 , C12N2830/002 , Y02A50/412 , Y02A50/466
摘要: The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses which contain a modified NS gene segment. Recombinant DNA techniques can be utilized to engineer site specific mutations into one or more noncoding regions of the viral genome which result in the down-regulation of one or more viral genes. Alternatively, recombinant DNA techniques can be used to engineer a mutation, including but not limited to an insertion, deletion, or substitution of an amino acid residue(s) or an epitope(s) into a coding region of the viral genome so that altered or chimeric viral proteins are expressed by the engineered virus.
-